{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:50Z","timestamp":1793957210912,"version":"4.8.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008795","name":"Manitoba Medical Service Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012854","name":"Children's Hospital Research Institute of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107950","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:23:57Z","timestamp":1790609037000},"page":"107950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prevalence of autoimmune comorbidities in aquaporin 4\u2013immunoglobulin G positive neuromyelitis optica spectrum disorder: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5645-9458","authenticated-orcid":false,"given":"Ninglu","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikjot","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5499-3396","authenticated-orcid":false,"given":"Karen","family":"Sayfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-6134","authenticated-orcid":false,"given":"Anibal","family":"Chertcoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-5595","authenticated-orcid":false,"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-8438","authenticated-orcid":false,"given":"Lucia B","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0001","doi-asserted-by":"crossref","first-page":"81EP","DOI":"10.1177\/1352458509353651","article-title":"Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics","volume":"16","author":"Adoni","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107950_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577236","article-title":"Risk factors of attacks in neuromyelitis optica spectrum disorders","volume":"343","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107950_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106787","article-title":"Comparative analysis of AQP4-IgG-positive and AQP4-IgG-negative NMOSD: a multicenter study in Latin America","volume":"104","author":"Alonso","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120460","article-title":"Predictors of overlapping autoimmune disease in neuromyelitis optica spectrum disorder (NMOSD): a retrospective analysis in two inner-city hospitals","volume":"443","author":"Alvarez","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107950_bib0005","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI manual for evidence synthesis. 2020th ed. https:\/\/synt.hesismanual.jbi.global."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0006","article-title":"Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran","volume":"77","author":"Ashtari","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/401739","article-title":"Anti-nuclear antibodies in daily clinical practice: prevalence in primary, secondary, and tertiary care","volume":"2014","author":"Avery","year":"2014","journal-title":"J. Immunol. Res."},{"issue":"3 SUPPL","key":"10.1016\/j.msard.2026.107950_bib0008","first-page":"118","article-title":"Frequency of comorbidities in neuromyelitis optica spectrum disorder","volume":"26","author":"Barzegar","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12883-016-0779-9","article-title":"Screening for onconeural antibodies in neuromyelitis optica spectrum disorders","volume":"17","author":"Berger","year":"2017","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107146","article-title":"Limited availability of live CBA for MOG-IgG testing and its consequences for the diagnosis and treatment of MOGAD in Latin American countries","volume":"109","author":"Boldrini","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107950_bib0011","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WNO.0000000000000403","article-title":"Neuromyelitis Optica spectrum disorder: disease course and long-term visual outcome","volume":"36","author":"Brody","year":"2016","journal-title":"J. Neuro-Ophthalmol."},{"key":"10.1016\/j.msard.2026.107950_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578591","article-title":"Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - a single center experience","volume":"403","author":"Cakan","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0013","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jcm13020355","article-title":"Relapses and serious infections in patients with Neuromyelitis Optica spectrum disorder treated with Rituximab: a Swedish single-center study","volume":"13","author":"Carlsson","year":"2024","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107950_bib0014","doi-asserted-by":"crossref","DOI":"10.1590\/0004-282X20140097","article-title":"Sj\u00f6gren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu","volume":"72","author":"Carvalho","year":"2014","journal-title":"Arq. Neuro-Psiquiatr."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/13524585211007086","article-title":"Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica","volume":"28","author":"Ciotti","year":"2022","journal-title":"Mult. Scler."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0022","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort","volume":"44","author":"Correa-D\u00edaz","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0016","unstructured":"Covidence. Published online 2025. Available at covidence.org."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort","volume":"122","author":"Dauby","year":"2022","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/0004-282x20160193","article-title":"Neuromyelitis optica: phenotypic characteristics in a Brazilian case series","volume":"75","author":"Del Negro","year":"2017","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"10.1016\/j.msard.2026.107950_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clineuro.2015.04.001","article-title":"Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre study","volume":"134","author":"Domingos","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0021","article-title":"Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: a single-center retrospective study","volume":"74","author":"Dresser","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3 SUPPL","key":"10.1016\/j.msard.2026.107950_bib0024","first-page":"118","article-title":"Burden of autoimmune comorbidity in patients with NMOSD in the United States revealed by retrospective commercial claims analysis","volume":"26","author":"Exuzides","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107950_bib0023","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2026.107950_bib0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0026","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-014-3066-3","article-title":"Neuromyelitis optica spectrum disorders associated with other autoimmune diseases","volume":"35","author":"Freitas","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0027","doi-asserted-by":"crossref","first-page":"223EP","DOI":"10.1007\/s13760-019-01176-6","article-title":"Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders","volume":"120","author":"Gkaniatsou","year":"2020","journal-title":"Acta Neurol. Belg."},{"issue":"3","key":"10.1016\/j.msard.2026.107950_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neurol.2025.01.002","article-title":"Retrospective, descriptive study of acute myelitis in French Guyana","volume":"181","author":"Grimont","year":"2025","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0029","article-title":"Cochrane handbook for systematic reviews of interventions. 6.4","author":"Higgins","year":"2023","journal-title":"Cochrane"},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.rdc.2026.02.001","article-title":"The Global rheumatology workforce: challenges and considerations","volume":"52","author":"Hsieh","year":"2026","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"4","key":"10.1016\/j.msard.2026.107950_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf293","article-title":"Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study","volume":"7","author":"Hsu","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2026.107950_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104023","article-title":"The description of neuromyelitis optica spectrum disorder: patient registry in Yangtze River Delta area of China","volume":"66","author":"Huang","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2026.107950_bib0033","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s40120-025-00794-y","article-title":"Incidence and risk factors for serious infections in patients with Neuromyelitis Optica spectrum disorder: a claims database study in Japan","volume":"14","author":"Isobe","year":"2025","journal-title":"Neurol. Ther."},{"issue":"7","key":"10.1016\/j.msard.2026.107950_bib0034","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica study group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107950_bib0035","doi-asserted-by":"crossref","first-page":"1135EP","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2026.107950_bib0036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1352458508088941","article-title":"Minor salivary gland inflammation in Devic\u2019s disease and longitudinally extensive myelitis","volume":"14","author":"Javed","year":"2008","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0037","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107950_bib0038","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s00415-017-8606-9","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis","volume":"264","author":"Kang","year":"2017","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107950_bib0039","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jnnp-2024-333644","article-title":"Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study. Journal of neurology","volume":"95","author":"Kim","year":"2024","journal-title":"Neurosurg. Psychiatry"},{"issue":"22","key":"10.1016\/j.msard.2026.107950_bib0040","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2026.107950_bib0041","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2013.3890","article-title":"Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies","volume":"70","author":"Kitley","year":"2013","journal-title":"JAMa Neurol."},{"issue":"101560960","key":"10.1016\/j.msard.2026.107950_bib0042","article-title":"Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)","volume":"16","author":"Kretschmer","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107950_bib0043","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107950_bib0044","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/JDRNTRUHS.JDRNTRUHS_65_20","article-title":"Relapsing neuromyelitis optica spectrum disorder","volume":"10","author":"Lavanya","year":"2021","journal-title":"J. Dr. NTR. Univ. Health Sci."},{"issue":"6","key":"10.1016\/j.msard.2026.107950_bib0045","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/13524585251328554","article-title":"Incidence and prevalence of neuromyelitis optica spectrum disorder in a contemporary, multi-ethnic cohort","volume":"31","author":"Lee","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107950_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123215","article-title":"Potential prognostic value of rheumatoid factor in anti-aquaporin 4-immunoglobin G-positive neuromyelitis optica spectrum disorders","volume":"466","author":"Lee","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"9451","key":"10.1016\/j.msard.2026.107950_bib0047","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2026.107950_bib0048","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-015-7844-y","article-title":"Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis","volume":"262","author":"Li","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0049","article-title":"Analysis of predictive risk factors in aquaporin-4-IgG positive highly active neuromyelitis optica spectrum disorders","volume":"12","author":"Li","year":"2021","journal-title":"Front. Neurol."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0050","article-title":"Clinical characteristics and prognosis of optic neuritis in Taiwan - a hospital-based cohort study","volume":"75","author":"Lin","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"101560960","key":"10.1016\/j.msard.2026.107950_bib0051","article-title":"The relationship between neuromyelitis optica spectrum disorder and autoimmune diseases","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Immunol."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0052","article-title":"Polyautoimmunity and multiple autoimmune syndrome in patients with neuromyelitis optica spectrum disorder","volume":"90","author":"Lopes","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3 Supplement","key":"10.1016\/j.msard.2026.107950_bib0053","first-page":"650","article-title":"Relation between neuromyelitis optica spectrum disorders and autoimmune systemic disease among the Mexican population","volume":"29","author":"Lopez","year":"2023","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0054","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12883-015-0417-y","article-title":"Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population","volume":"15","author":"Mao","year":"2015","journal-title":"BMC. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107950_bib0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107950_bib0056","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","article-title":"Familial neuromyelitis optica","volume":"75","author":"Matiello","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2026.107950_bib0058","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107950_bib0067","author":"NCT01892345"},{"issue":"7","key":"10.1016\/j.msard.2026.107950_bib0059","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40263-025-01191-7","article-title":"Long-term effectiveness and safety of Rituximab in Neuromyelitis Optica spectrum disorder: a 5-year observational study","volume":"39","author":"Novi","year":"2025","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2026.107950_bib0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ. Publ."},{"key":"10.1016\/j.msard.2026.107950_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103252","article-title":"Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort","volume":"56","author":"Paolilo","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107950_bib0062","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2018-320249","article-title":"Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders","volume":"90","author":"Papadopoulou","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"5","key":"10.1016\/j.msard.2026.107950_bib0063","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209147","article-title":"Mortality of the danish nationwide AQP4 antibody-seropositive neuromyelitis optica spectrum disorder patient cohort","volume":"102","author":"Papp","year":"2024","journal-title":"Neurology"},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0084","article-title":"Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries","volume":"51","author":"Papp","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107950_bib0064","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.msard.2026.107950_bib0057","unstructured":"Meta-Analysis of Proportions App (PERSystMA). Published online 2026. Available at https:\/\/persyst.group\/persystma\/."},{"issue":"8","key":"10.1016\/j.msard.2026.107950_bib0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0066","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort","volume":"74","author":"Rajput","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2026.107950_bib0068","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209888","article-title":"Eculizumab use in Neuromyelitis Optica spectrum disorders: routine clinical care data from a European cohort","volume":"103","author":"Ringelstein","year":"2024","journal-title":"Neurology"},{"issue":"4\u20135","key":"10.1016\/j.msard.2026.107950_bib0069","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/13524585231151953","article-title":"A national case-control study investigating demographic and environmental factors associated with NMOSD","volume":"29","author":"Rotstein","year":"2023","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2026.107950_bib0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00415-025-13180-3","article-title":"The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD","volume":"272","author":"Samadzadeh","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578446","article-title":"Spectrum of auto-antibodies in NMO and MOG associated CNS demyelination- the SANMAD study","volume":"396","author":"Samim","year":"2024","journal-title":"J. Neuroimmunol."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0072","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","volume":"56","author":"Santos","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0073","article-title":"Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia","volume":"85","author":"Sechi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0074","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107950_bib0075","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0076","article-title":"Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry","volume":"38","author":"Shosha","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2026.107950_bib0077","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","article-title":"AQP4 antibody-positive Thai cases: clinical features and diagnostic problems","volume":"77","author":"Siritho","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107950_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1416493","article-title":"A comparative study on anti-MOG and anti-AQP4 associated optic neuritis following mild COVID-19: insights from a Chinese single-center experience","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111137","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China","volume":"135","author":"Sun","year":"2025","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10072-023-07050-x","article-title":"Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients","volume":"45","author":"Szilasiova","year":"2024","journal-title":"Neurol. Sci."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0081","article-title":"The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: a population-based study","volume":"70","author":"Tisavipat","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0082","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107950_bib0017","article-title":"Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: about one in a million","volume":"2","author":"Van Pelt","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"101580247","key":"10.1016\/j.msard.2026.107950_bib0083","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2017.07.013","article-title":"Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: a comparison between Thai and American-caucasian cohorts","volume":"17","author":"Vanikieti","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107950_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106719","article-title":"Neuromyelitis optica spectrum disorders and their overlap with myasthenia gravis in a single center in Argentina","volume":"103","author":"Villa","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0086","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107950_bib0087","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2026.107950_bib0088","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0089","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2026.107950_bib0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-025-03538-3","article-title":"Concomitant Sj\u00f6gren\u2019s disease in patients with NMOSD: impacts on neurologic disease severity and recurrence","volume":"27","author":"Wu","year":"2025","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0091","first-page":"159","article-title":"Clinical features of Neuromyelitis Optica spectrum disorders with connective tissue diseases","volume":"43","author":"Xie","year":"2021","journal-title":"Zhongguo. Yi Xue. Ke. Xue Yuan. Xue. Bao. Acta Acad. Med. Sin."},{"key":"10.1016\/j.msard.2026.107950_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.969762","article-title":"Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease","volume":"13","author":"Yao","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107950_bib0093","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10072-016-2751-2","article-title":"Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sj\u00f6gren\u2019s syndrome","volume":"38","author":"Zhong","year":"2017","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:40:06Z","timestamp":1793954406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":93,"alternative-id":["S2211034826009855"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107950","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of autoimmune comorbidities in aquaporin 4\u2013immunoglobulin G positive neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107950"}}